This report contains detailed information about the company's business finances and management.
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 42.73 | 0.00 0.00% | 2.06% | 990 | 7.0M |
Editor Note: For more information about this release, please scroll to bottom. LONDON, July 21, 2014 /PRNewswire/ -- On Friday, July 18, 2014, the NASDAQ Composite ended at 4,432.15, up 1.57%, the Dow Jones Industrial Average advanced 0.73%, to finish the day at 17,100.18, and the S&P; 500 closed at 1,978.22, up 1.03%. The gains were broad based with all the ten sectors ending the session in positive. The S&P; 500 Health Care Sector Index ended the day at 710.68, up 1.63%, with the index advancing 6.63% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Stryker Corporation (NYSE: SYK), Zimmer Holdings Inc. (NYSE: ZMH), and EnteroMedics Inc. (NASDAQ: ETRM). Free research on these five companies can be accessed at:
Operations before taxes 1,160 655 1,815 Taxes on Earnings from Continuing Operations 361 (16) 345 Net Earnings from Continuing
Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, as described below $0.54 $0.46 17.4 3) ====== ======
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. In August 2013, Abbott Laboratories completed its acquisition of OptiMedica Corporation. In August 2013, Abbott Laboratories completed its acquisition of IDEV Technologies.
| Bid/Size | Ask/Size |
|---|---|
| -- / -- | -- / -- |
| Price Open | Previous Close |
|---|---|
| 0.00 | 42.73 |
| Day High | Day Low |
|---|---|
| -- | -- |
| 52wk High/Date | 52wk Low/Date |
|---|---|
| 42.99 / 7/17/2014 | 32.70 / 9/3/2013 |
| % off 52wk High | % off 52wk Low |
|---|---|
| -0.60% | 30.67% |
| Beta (5 Yr) | Market Capitalization |
|---|---|
| 0.6 | 64.2B Large Cap |
| Shares Outstanding | Volatility Avg |
|---|---|
| 1.5B | 16.69 |
| EPS(TTM) | P/E Ratio |
|---|---|
| 1.39 | 30.7 |
| Dividend Announcement | Dividend Yield |
|---|---|
| 6/13/2014 | 2.06% |
| Ex-Date | Date of Record |
|---|---|
| 7/11/2014 | 7/15/2014 |
| Payable | Payable Date |
|---|---|
| 0.22 - QRTR | 8/15/2014 |
| Peers | |
|---|---|
ABT Abbott Laboratories | 11.48% |
Johnson & Johnson | 11.15% |
Pfizer Inc. | 0.33% |
Merck & Co., Inc. | 16.56% |
Eli Lilly and Co | 24.45% |
ABT Abbott Laboratories | 2.06% |
Johnson & Johnson | 2.75% |
Pfizer Inc. | 3.38% |
Merck & Co., Inc. | 3.02% |
Eli Lilly and Co | 3.09% |
ABT Abbott Laboratories | 0.00% |
Johnson & Johnson | 0.00% |
Pfizer Inc. | 0.00% |
Merck & Co., Inc. | 0.00% |
Eli Lilly and Co | 0.00% |